Cap problem leads to recall

recall regulatory
Anticonvulsant recalled due to issue with child-resistant caps Pfizer Australia, in consultation with the TGA, has initiated a recall for product correction for bottles of phenytoin 30 mg capsules, 100 mg capsules and 50 mg tablets, which are marketed under the brand name Dilantin. According to advice provided by the TGA bottles of Dilantin may

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Forum: PPIs and increased risk of stroke?
Next One-third of dementia burden may be preventable